Kevin M Weiss1, Jeb S Jones1, David A Katz2,3, Thomas L Gift4, Kyle Bernstein4, Kimberly Workowski4,5, Eli S Rosenberg1,6, Samuel M Jenness1. 1. From the Department of Epidemiology, Emory University, Atlanta, GA. 2. Department of Global Health, University of Washington. 3. HIV/STD Program, Public Health-Seattle & King County, Seattle, WA. 4. Division of STD Prevention, Centers for Disease Control and Prevention. 5. Department of Medicine, Emory University, Atlanta, GA. 6. Department of Epidemiology and Biostatistics, University of Albany, Albany, NY.
Abstract
BACKGROUND: Expedited partner therapy (EPT) is an intervention for patients with gonorrhea or chlamydia, providing index patients with prescriptions or medication to give to their partners. Expedited partner therapy is recommended for heterosexuals but not for men who have sex with men (MSM), partially due to concerns about overtreatment of uninfected partners and missed opportunities for human immunodeficiency virus (HIV) diagnosis. METHODS: We extended our stochastic network-based mathematical model of HIV, gonorrhea, and chlamydia among MSM to include EPT. The EPT implementation was simulated for 10 years. Counterfactual scenarios varied EPT coverage, provision, uptake, and partnership window duration. We estimated sexually transmitted infection (STI) incidence, proportion of infections averted, and process outcomes under each scenario. RESULTS: Delivery of EPT to 20% of eligible MSM index patients (coverage) reduced cumulative STI incidence by 27% (interquartile range, 13%-39%) over 10 years compared with current estimated STI screening levels. A 20% increase in providing medication to non-index partners (provision) averted 32% (interquartile range, 20%-41%) of STI infections compared with estimated STI screening levels. When targeted by partnership type, EPT solely to casual partners maximized the population-level infections averted. The proportion of partners given medication who had no current STI varied from 52% to 63%, depending on coverage level. The proportion of partners given medication with undiagnosed HIV infection was 4% across scenarios. CONCLUSIONS: Expedited partner therapy could reduce bacterial STI incidence for MSM. However, this intervention could result in missed opportunities for HIV/STI prevention and a substantial increase in use of antimicrobials by STI-uninfected MSM, raising concerns about cost and antimicrobial resistance.
BACKGROUND: Expedited partner therapy (EPT) is an intervention for patients with gonorrhea or chlamydia, providing index patients with prescriptions or medication to give to their partners. Expedited partner therapy is recommended for heterosexuals but not for men who have sex with men (MSM), partially due to concerns about overtreatment of uninfected partners and missed opportunities for human immunodeficiency virus (HIV) diagnosis. METHODS: We extended our stochastic network-based mathematical model of HIV, gonorrhea, and chlamydia among MSM to include EPT. The EPT implementation was simulated for 10 years. Counterfactual scenarios varied EPT coverage, provision, uptake, and partnership window duration. We estimated sexually transmitted infection (STI) incidence, proportion of infections averted, and process outcomes under each scenario. RESULTS: Delivery of EPT to 20% of eligible MSM index patients (coverage) reduced cumulative STI incidence by 27% (interquartile range, 13%-39%) over 10 years compared with current estimated STI screening levels. A 20% increase in providing medication to non-index partners (provision) averted 32% (interquartile range, 20%-41%) of STI infections compared with estimated STI screening levels. When targeted by partnership type, EPT solely to casual partners maximized the population-level infections averted. The proportion of partners given medication who had no current STI varied from 52% to 63%, depending on coverage level. The proportion of partners given medication with undiagnosed HIV infection was 4% across scenarios. CONCLUSIONS: Expedited partner therapy could reduce bacterial STI incidence for MSM. However, this intervention could result in missed opportunities for HIV/STI prevention and a substantial increase in use of antimicrobials by STI-uninfected MSM, raising concerns about cost and antimicrobial resistance.
Authors: Sally C Stephens; Kyle T Bernstein; Mitchell H Katz; Susan S Philip; Jeffrey D Klausner Journal: Sex Transm Dis Date: 2010-08 Impact factor: 2.830
Authors: Matthew R Golden; William L H Whittington; H Hunter Handsfield; James P Hughes; Walter E Stamm; Matthew Hogben; Agnes Clark; Cheryl Malinski; Jennifer R L Helmers; Katherine K Thomas; King K Holmes Journal: N Engl J Med Date: 2005-02-17 Impact factor: 91.245
Authors: Patricia Kissinger; Hamish Mohammed; Gwangi Richardson-Alston; Jami S Leichliter; Stephanie N Taylor; David H Martin; Thomas A Farley Journal: Clin Infect Dis Date: 2005-07-19 Impact factor: 9.079
Authors: Patricia J Kissinger; Kathleen Reilly; Stephanie N Taylor; Jami S Leichliter; Susan Rosenthal; David H Martin Journal: Sex Transm Dis Date: 2009-08 Impact factor: 2.830
Authors: Alfonso C Hernández-Romieu; Patrick S Sullivan; Richard Rothenberg; Jeremy Grey; Nicole Luisi; Colleen F Kelley; Eli S Rosenberg Journal: Sex Transm Dis Date: 2015-09 Impact factor: 2.830
Authors: Jesse L Clark; Eddy R Segura; Catherine E Oldenburg; Jessica Rios; Silvia M Montano; Amaya Perez-Brumer; Manuel Villaran; Jorge Sanchez; Thomas J Coates; Javier R Lama Journal: BMC Med Date: 2017-05-04 Impact factor: 8.775
Authors: Emily A Groene; Christy M Boraas; M Kumi Smith; Sarah M Lofgren; Meghan K Rothenberger; Eva A Enns Journal: Sex Transm Dis Date: 2022-07-04 Impact factor: 3.868
Authors: Deven T Hamilton; Clara Agutu; Joseph B Babigumira; Elise van der Elst; Amin Hassan; Evanson Gichuru; Peter Mugo; Carey Farquhar; Thumbi Ndung'u; Martin Sirengo; Wairimu Chege; Steven M Goodreau; Adam Elder; Eduard J Sanders; Susan M Graham Journal: J Acquir Immune Defic Syndr Date: 2022-05-05 Impact factor: 3.771
Authors: Xianglong Xu; Eric P F Chow; Jason J Ong; Christian J P A Hoebe; Zhuoru Zou; Jane S Hocking; Christopher K Fairley; Lei Zhang Journal: BMC Med Date: 2020-11-17 Impact factor: 8.775